Cellectis: First-Half 2014 Financial Results
PARIS--(BUSINESS WIRE)--Regulatory News:
Cellectis SA (Paris:ALCLS) (Alternext: ALCLS.PA), an expert in developing immunotherapies based on engineered allogeneic CART cells (UCART), presents its first-half 2014 consolidated financial statements to June 30, 2014, approved by the Board of Directors at its meeting held on September 29.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.